StocksMedium•5 November 2026•
1 min read
ADMA Biologics Raises 2026 EBITDA Guidance on Strong ASCENIV Demand
Key Facts
1ADMA Biologics raised its minimum 2026 adjusted EBITDA guidance to at least $275 million.
2The company reiterated its 2026 revenue guidance of at least $530 million.
3The guidance raise is driven by accelerating demand for the company's ASCENIV product.
ADMA Biologics raised its minimum 2026 adjusted EBITDA guidance to at least $275 million. Seeking Alpha reported that the company reiterated its revenue outlook for the same year at a minimum of $530 million. The upward revision is driven by accelerating demand for the company's ASCENIV product.
ADMA closed at $10.48 on November 4, 2026, after reaching a session high of $11.49 and a low of $10.25. The increased profitability guidance, while maintaining revenue targets, indicates improved margins and strong market traction for its core offerings.